Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

924

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Malaria
Interventions
DRUG

Dihydroartemisinin-piperaquine (DP)

Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.

OTHER

DP Placebo

Placebos will be identical appearance to DP.

Trial Locations (1)

Unknown

IDRC - Tororo Research Clinic, Tororo

All Listed Sponsors
collaborator

Stanford University

OTHER

collaborator

Infectious Diseases Research Collaboration, Uganda

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Karolinska Institutet

OTHER

lead

Grant Dorsey, M.D, Ph.D.

OTHER